“The present problem has uncovered some structural weaknesses inside the EU’s medicines supply chain and also a superior dependence on non-EU nations around the world for active pharmaceutical ingredients,” Kyriakides claimed. She suggested that supply chain challenges be addressed in an EU pharmaceutical strategy anticipated to generally be